Safety and Efficacy of Triple Combination Therapy in Patients With Glaucoma or Ocular Hypertension

A Multicenter, Open-label Study to Evaluate the Safety and Efficacy of Twice-daily 0.01% Bimatoprost/0.15% Brimonidine/0.5% Timolol Ophthalmic Solution (Triple Combination) in Patients in India, Who Have Glaucoma or Ocular Hypertension With Elevated IOP, and Are on Twice-daily 0.2% Brimonidine/0.5% Timolol Ophthalmic Solution (Dual Combination) Therapy

This study will investigate the safety and efficacy of Triple Combination Therapy (bimatoprost/brimonidine tartrate/timolol fixed combination ophthalmic solution) in patients with glaucoma or ocular hypertension who have elevated intraocular pressure (IOP) on brimonidine/timolol ophthalmic solution.

Inclusion Criteria:

• Glaucoma and/or ocular hypertension in both eyes
• Requires IOP-lowering treatment in both eyes

Exclusion Criteria:

• Other active ocular disease other than glaucoma or ocular hypertension (eg, uveitis, ocular infections or severe dry eye)
• Current or anticipated use of ocular medications other than study medications, except for intermittent use of artificial tears
• Use of oral, injectable or topical corticosteroids within 21 days
• Iridectomy or laser peripheral iridotomy in the study eye within 3 months
• Uncomplicated cataract surgery in the study eye within 6 months
• Incisional glaucoma surgery in the study eye within 12 months